季鸣，副研究员，北京大学药学本科，北京协和医学院分子生物学和生物化学硕士，药理学博士，2018年奥地利科学院生物技术研究所visiting scientist。
曾先后任职于北京依格斯医疗科技有限公司、辉瑞制药有限公司，负责多个新药在中国临床开发和上市注册，涉及治疗领域包括心血管药物、泌尿系统药物、妇科药物、眼科药物、抗感染和抗艾滋病毒药物等。
现就职于中国医学科学院药物研究所药理室，先后主持和参与多个国家自然基金、院校级基金，发表sci文章20多篇，申请专利20多个，参与4个1类新药研发。
主要研究方向为肿瘤药理和抗肿瘤小分子药物开发，涉及细胞毒类、分子靶向和肿瘤免疫治疗药物。
（1）肿瘤新靶点的发现：与国内外研究机构展开合作，针对肿瘤新靶点如ddx3开展作用机制研究，在此基础上针对新靶点开展药物研发。
（2）生物标志物的寻找：立足于在研药物，通过寻找生物标志物，为药物开发提供指导，如发现ras突变是决定口服微管/stat3双靶点抑制剂imm-h020疗效的重要标志物、肿瘤脂肪酸合成过度活化可能是导致parp抑制剂疗效不佳的重要因素等。
（3）独特技术平台的建立：建立了国内具有独特优势的脑部肿瘤/肿瘤脑转移治疗药物原位药效评价平台。利用该平台，先后推进了药物研发。
1. a novel pi3k inhibitor xh30 suppresses orthotopic glioblastoma and brain metastasis in mice models. ming ji#, dongjie wang#, songwen lin, chunyang wang, ling li, zhihui zhang, jing jin1, deyu wu1, yi dong, heng xu*, duo lu *, xiaoguang chen*. 2021 online
2. design, synthesis, and biological evaluation of a novel photocaged pi3k inhibitor toward precise cancer treatment. kehui zhang*, ming ji*, songwen lin, shouguo peng, zhihui zhang, mingyi zhang, jingbo zhang,yan zhang, deyu wu, hua tian, xiaoguang chen and heng xu. j. med. chem. 2021 online.
3. sphingosine-1-phosphate receptor subtype 1 (s1p1) modulator immh001 regulates adjuvant- and collagen-induced arthritis. jin j*, ji m*, fu r, wang m, xue n, xiao q, hu j, wang x, lai f, yin d, chen x. front pharmacol. 2019.
4. cat3, a prodrug of 13a(s)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the hedgehog signaling pathway, independently of o6-methylguanine dna methyltransferase expression. ji m, wang l, chen j, xue n, wang c, lai f, wang r, yu s, jin j, chen x. onco targets ther. 2018, 11:3671-3684.
5. the development of a biotinylated nad -applied human poly(adp-ribose) polymerase 3 (parp3) enzymatic assay. ji m*, wang l*, xue n, lai f, zhang s, jin j, chen x. slas discov. 2018.
6. discovery of quinazoline-2,4(1h,3h)-dione derivatives as novel parp-1/2 inhibitors: design, synthesis and their antitumor activity. jie zhou*, ming ji*, haiping yao, ran cao, hailong zhao, xiaoyu wang, xiaoguang chen and bailing xu. org biomol chem. 2018.
7. validating a selective s1p1 receptor modulator syl930 for psoriasis treatment. ji m*, xue n, lai f, zhang x, zhang s, wang y, jin j, chen x. biol pharm bull. 2018.
8. poly (adp-ribose) polymerases inhibitor, zj6413, as a potential therapeutic agent against breast cancer. zhou q*, ji m*, zhou j, jin j, xue n, chen j, xu b, chen x. biochem pharmacol. 2016.
9. discovery of novel quinazoline-2,4(1h,3h)-dione derivatives as potent parp-2 selective inhibitors. zhao h*, ji m*, cui g, zhou j, lai f, chen x, xu b. bioorg med chem. 2017.
10. discovery of 2-substituted 1h-benzo[d]immidazole-4-carboxamide derivatives as novel poly(adp-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. zhou j*, ji m*, zhu z, cao r, chen x, xu b. eur j med chem. 2017.
11. discovery of 1-substituted benzyl-quinazoline-2,4(1h,3h)-dione derivatives as novel poly(adp-ribose)polymerase-1 inhibitors. yao h*, ji m*, zhu z, zhou j, cao r, chen x, xu b. bioorg med chem. 2015.
1. 溴代苄醚衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,张莉婧,杨阳,来芳芳,季鸣,周川,郑义,薛妮娜,李凌。中国专利号zl2017800319432，授权公告日 2021/5/4
2. 一类抗肿瘤天然产物ecteinascidins结构类似物的制备和医药用途。刘站柱,陈晓光,鲁向冉,潘璇,季鸣,贯宝和。中国专利号zl2018102983674，授权公告日 2021/4/13
3. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。美国专利号us10975049b2，授权公告日 2021/4/13
4. 含有哌嗪酮的喹唑啉酮类parp-1/2抑制剂及其制作方法、药物组合物和用途。徐柏玲、陈晓光、周洁、季鸣、姚海平、周秦。中国专利号zl201610108263.3， 授权公告日 2020/7/14
5. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。俄罗斯专利号ru2735541c2， 授权公告日 2020/11/3
